middle.news
Paradigm Biopharma Boosts Cash by $6.3M to Power Osteoarthritis Trial
8:59am on Friday 24th of January, 2025 AEDT
•
Pharmaceuticals
Read Story
Paradigm Biopharma Boosts Cash by $6.3M to Power Osteoarthritis Trial
8:59am on Friday 24th of January, 2025 AEDT
Key Points
Received $6.3 million R&D Tax Incentive refund for FY24
Cash reserves now approximately $31 million
Advancing Phase 3 osteoarthritis clinical trial with recruitment planned for Q1 2025
Raised $16 million capital in December 2024
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE